Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

KURA stock hub

Kura Oncology, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KURAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

836.1M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KURA

In the news

Latest news · KURA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-94.8

P25 -105.6P50 -46.5P75 -3.1

ROIC-60.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KURA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

206

Groups with data

Currency

USD

Showing 206 of 206 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001422143
Company name	Kura Oncology, Inc.
Country	United States
Country code	US
Cusip	50127T109
Employees	260
Employees Change	68%
Employees Change Percent	35.42
Enterprise value	$189.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US50127T1097
Last refreshed	2026-05-10
Market cap	$836.1M
Market cap category	Small-Cap
Price	$9.42
Price currency	USD
Rev Per Employee	259,546.15x
Sector	Healthcare
Sic	2834
Symbol	KURA
Website	https://kuraoncology.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-33.33%
EV Sales Forward	1.72x
EV/Sales	2.81x
FCF yield	-8.46%
P/B ratio	4.75x
P/S ratio	12.39x
PS Forward	7.6x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	-272.15%
Gross Profit	$-183.6M
Net Income	$-278.7M
Net Income Growth Years	0%
Pretax Margin	-412.51%
Profit Per Employee	$-1.1M
ROA	-25.33
Roa5y	-19.95
ROCE	-48.86
ROE	-94.82
Roe5y	-45.55
ROIC	-60.74

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	13.04%
Cagr1y	66.93%
Cagr3y	-6.13%
Cagr5y	-18.47%
EPS Growth Years	0
FCF Growth Q	-57.23%
OCF Growth Q	-56.43%
Revenue Growth	25.24x
Revenue Growth Q	-67.83x
Revenue Growth Years	1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.09
Assets	$738.4M
Cash	$667.2M
Current Assets	$708.7M
Current Liabilities	$117M
Debt	$20.5M
Debt Equity	$0.12
Equity	$174.1M
Interest Coverage	-200.8
Liabilities	$564.2M
Long Term Assets	$29.7M
Long Term Liabilities	$447.3M
Net Cash	$646.8M
Net Cash By Market Cap	$77.35
Net Cash Growth	-9.01%
Net Debt Equity	$-3.71
Tangible Book Value	$174.1M
Tangible Book Value Per Share	$1.98
WACC	5.99

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.06
Net Working Capital	$-74.3M
Quick ratio	5.81
Working Capital	$591.7M
Working Capital Turnover	$0.11

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.76%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	240.69%
1Y total return	66.87%
200-day SMA	8.99
3Y total return	-17.3%
50-day SMA	8.82
50-day SMA vs 200-day SMA	50under200
5Y total return	-63.98%
All Time High	43
All Time High Change	-78.09%
All Time High Date	2020-12-09
All Time Low	2.5
All Time Low Change	276.8%
All Time Low Date	2016-07-05
ATR	0.41
Beta	0.32
Beta1y	1.29
Beta2y	1.39
Ch YTD	-9.34
High	9.51
High52	12.49
High52 Date	2025-11-14
High52ch	-24.58%
Low	9.33
Low52	5.45
Low52 Date	2025-08-11
Low52ch	72.84%
Ma50ch	6.78%
Premarket Change Percent	0.75
Premarket Price	$9.39
Premarket Volume	545
Price vs 200-day SMA	4.83%
RSI	57.42
RSI Monthly	46.36
RSI Weekly	53.25
Sharpe ratio	1.1x
Sortino ratio	1.9
Total Return	-1.76%
Tr YTD	-9.34
Tr1m	6.8%
Tr1w	7.41%
Tr3m	20.31%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	10
Analyst Count Top	1
Analyst Price Target Top	$28
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.8
Earnings Revenue Estimate	23,747,000x
Earnings Revenue Estimate Growth	68.32x
Operating Income	$-303.6M
Operating margin	-449.9
Price target	$27.38
Price Target Change	$191
Price Target Change Top	$197

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	65,275,666%
Float Percent	73.54%
Shares Insiders	1.53%
Shares Institutions	72.79%
Shares Out	88,762,704
Shares Qo Q	0.46%
Shares Yo Y	1.76%
Short Float	22.99%
Short Ratio	11.1
Short Shares	16.91

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-107.8M
Average Volume	1,214,010.2x
Bv Per Share	1.98
CAPEX	$-6.6M
Ch10y	240.7
Ch1m	6.8
Ch1w	7.41
Ch1y	66.87
Ch3m	20.31
Ch3y	-17.3
Ch5y	-63.98
Ch6m	-4.46
Change	1.07%
Change From Open	0.75
Close	9.32
Days Gap	0.32
Depreciation Amortization	1,032,000
Dollar Volume	8,373,654.7
Earnings Date	2026-05-12
Earnings Time	amc
EBIT	$-303.6M
EBITDA	$-302.6M
EPS	$-3.18
F Score	2
FCF	$-70.7M
FCF EV Yield	-37.33x
FCF Per Share	$-0.8
Financing CF	1,793,000
Fiscal Year End	December
Founded	2,014
Income Tax	$297,000
Investing CF	-13,098,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-05
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-05
Ma150	9.48
Ma150ch	-0.61%
Ma20	9.2
Ma20ch	2.42%
Net CF	-75,363,000
Next Earnings Date	2026-05-12
Open	9.35
Optionable	Yes
Position In Range	50
Post Close	9.42
Postmarket Change Percent	-0.21
Postmarket Price	$9.4
Ppne	15,157,000
Pre Close	9.32
Price Date	2026-05-08
Ptbv Ratio	4.8
Relative Volume	0.73x
Revenue	67,482,000x
SBC By Revenue	54.99x
Share Based Comp	37,108,000
Tax By Revenue	0.44x
Tr6m	-4.46%
Us State	California
Volume	888,923
Z Score	-1.82

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KURA pay a dividend?

Capital-return profile for this ticker.

Performance

KURA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KURA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+72.8%

Float: +73.5% of shares outstanding

Insider ownership

+1.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

KURA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

57.4

Neutral momentum band

Price vs 200-day MA

+4.8%

50/200-day relationship not available

Beta (5Y)

0.32

Less volatile than the market

Sharpe ratio

1.10

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KURA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KURA stock rating?

Kura Oncology, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KURA analysis?

The full report lives at /stocks/KURA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KURA?

The latest report frames KURA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KURA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.